Tiny molecule may help battle depression

Image
Press Trust of India Toronto
Last Updated : Jun 09 2014 | 12:33 PM IST
A tiny molecule may provide a marker for depression and help detect individuals who are likely to respond to antidepressant treatment, a new study has found.
Researchers at McGill University and the Douglas Institute in Canada discovered that levels of a small molecule, called miR-1202, found only in humans and in other primates are lower in the brains of depressed individuals.
Depression is a common cause of disability, and while viable medications exist to treat it, finding the right medication for individual patients often amounts to trial and error for the physician.
"Using samples from the Douglas Bell-Canada Brain Bank, we examined brain tissues from individuals who were depressed and compared them with brain tissues from psychiatrically healthy individuals," said Dr Gustavo Turecki, a psychiatrist at the Douglas and professor in the Faculty of Medicine, Department of Psychiatry at McGill.
"We identified this molecule, a microRNA known as miR-1202, only found in humans and primates and discovered that it regulates an important receptor of the neurotransmitter glutamate," said Turecki.
Turecki and colleagues conducted a number of experiments that showed that antidepressants change the levels of this microRNA.
"In our clinical trials with living depressed individuals treated with citalopram, a commonly prescribed antidepressant, we found lower levels in depressed individuals compared to the non-depressed individuals before treatment," said Turecki.
"Clearly, microRNA miR-1202 increased as the treatment worked and individuals no longer felt depressed," Turecki said.
"Although antidepressants are clearly effective, there is variability in how individuals respond to antidepressant treatment," said Turecki.
"We found that miR-1202 is different in individuals with depression and particularly, among those patients who eventually will respond to antidepressant treatment," he said.
The study was published in the journal Nature Medicine.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 09 2014 | 12:33 PM IST

Next Story